论文部分内容阅读
[目的]探讨肿瘤干细胞标记物分化抗原簇蛋白133(CD133)和微血管密度(micro vessel density,MVD)在三阴乳腺癌(triple negative breast carcinoma,TNBC)组织标本中的表达及其意义.[方法]选择2010年1月至2012年1月本院诊治的TNBC患者41例,采用免疫组织化学法ElivisionTMplus检测CD133表达和MVD计数,并分析其与临床参数的相关性.[结果]41例TNBC患者中CD133表达阳性者18例,占43.90%,其中肿瘤大小、临床分期及淋巴结转移与CD133阳性率密切相关(P<0.05);MVD值在淋巴结转移及临床分期中比较差异有统计学意义(P<0.05);TNBC患者中CD133表达阳性者的MVD值为(23.34±8.4),明显高于CD133表达阴性者的(18.11±5.5),其差异有统计学意义(t=2.403,P<0.05);TNBC中CD133阳性表达者的无瘤生存时间(DFS)、总体生存时间(OS)分别为(25.5±3.6)个月、(32.3±2.5)个月,明显低于CD133阴性表达者的(58.2±4.2)个月、(54.6±3.3)个月,其差异均有统计学意义(t=26.308,P<0.05;t=23.796,P<0.05);以本研究41例TNBC患者的MVD的中位值21为分界线,结果显示MVD值≥21的3年和5年生存率均显著低于MVD值<21的3年和5年生存率,其差异有统计学意义(P<0.05).[结论]CD133表达和MVD值与TNBC患者的淋巴转移及临床分期密切相关,其可判断TNBC患者的疾病进展及预后,具有较高的临床价值.“,”[Objective]To detect the expression of tumor stem cell marker CD133 and micro vessel density (MVD)in triple negative breast carcinoma(TNBC),and to analyze their clinical value.[Methods]A total of 41 patients with triple-negative breast cancer were enrolled in our hospital from January 2010 to January 2012 for this study.CD133 expression and MVD count were measured by immunohistochemical method ElivisionTM plus,and the follow-up data of all patients were arranged and analyzed.[Results]There were significant differences in age, menstrual status,lymph node metastasis and histological grade between TNBC patients and non-TNBC patients (P 0.05).Out of the total 41 TNBC cases,18 had CD133 positive expression,accounting for 43.90% of the total samples.In these cases,the tumor size,clinical stage and lymph node metastasis were closely related to the posi-tive rate of CD133(P <0.05).The mean MVD count of TNBC patients was(20.95 ± 7.8)which was signifi-cantly higher than that of non-TNBC group(15.02 ± 9.3);the difference was significant(t = 3.916,P <0.05). MVD counts in lymph node metastasis and clinical staging were statistically significant(P <0.05).The MVD val-ue of CD133 positive in TNBC patients was(23.34 ± 8.4),which was significantly higher than that of CD133 negative(18.11 ± 5.5),and the difference was significant(t =2.403,P <0.05).The mean time of disease-free survival(DFS)and overall survival(OS)time of CD133 positive expression in TNBC were(25.5 ± 3.6)months and(32.3 ± 2.5)months,respectively.These were significantly lower than those of CD133 negative expression in TNBC DFS(58.2 ± 4.2)months and OS(54.6 ± 3.3)months,respectively;The difference was significant(P<0.05).In this study,the median value of MVD in 41 patients with TNBC was 21.Our results showed that the 3-year and 5-year survival rates of MVD ≥21 were significantly lower than those of MVD<21;the difference was significant(P <0.05).[Conclusion]CD133 expression and M VD count are closely related to lymphatic metastasis and clinical stage in TNBC patients.Therefore,the clinical progress and prognosis of TNBC patients can be deter-mined by measuring CD133 expression and MVD count and is worthy of clinical application.